supplementary figure 1
DESCRIPTION
Lovastatin. 0 µM. 2.5 µM. 5 µM. 10 µM. 25 µM. 50 µM. 80. % apoptosis. 70. 60. 50. 40. 30. Docetaxel. 0nM. 20. 24h. 48h. 72h. 96h. 1nM. 2.5nM. 5nM. 10. 7.5nM. 10nM. %apoptosis. 70. 0. 60. 50. 40. 30. 20. 10. 0. 24h. 48h. 72h. A. B. Supplementary Figure 1. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Supplementary Figure 1](https://reader036.vdocuments.net/reader036/viewer/2022062423/56814901550346895db63154/html5/thumbnails/1.jpg)
Supplementary Figure 1
0
10
20
30
40
50
60
70
24h 48h 72h
%ap
op
tosi
s
0nM1nM2.5nM5nM7.5nM10nM
Docetaxel
0
10
20
30
40
50
60
70
80
24h 48h 72h 96h
% a
po
pto
sis
0 µM2.5 µM5 µM10 µM25 µM50 µM
LovastatinA
B
![Page 2: Supplementary Figure 1](https://reader036.vdocuments.net/reader036/viewer/2022062423/56814901550346895db63154/html5/thumbnails/2.jpg)
HepG2
0
2
4
6
8
10
12
14
control L 12.5µM D 5nM L 12.5µM+ D 5nM
Cas
pas
e 3/
7 ac
tivi
ty
(arb
itra
ry u
nit
s)
H322
0123456789
control L 12.5µM D 5nM L 12.5µM + D 5nM
Cas
pas
e 3/
7 ac
tivi
ty
(arb
itra
ry u
nit
s)
24 h48 h
HeLa
0123456789
control L 12.5µM D 5nM L 12.5µM+ D 5nM
Cas
pas
e 3/
7 ac
tivi
ty
(arb
itra
ry u
nit
s)
Supplementary Figure 2
![Page 3: Supplementary Figure 1](https://reader036.vdocuments.net/reader036/viewer/2022062423/56814901550346895db63154/html5/thumbnails/3.jpg)
0
10
20
30
40
50
60
70
80
% a
po
pto
sis
control L 12.5µM V 0.5nML 12.5µM+ V 0.5nM
V 1nML 12.5µM+ V 1nM
***
***
***
***
***
† †
# # #
# #
† †
Supplementary Figure 3
![Page 4: Supplementary Figure 1](https://reader036.vdocuments.net/reader036/viewer/2022062423/56814901550346895db63154/html5/thumbnails/4.jpg)
Supplementary Figure 4
******# # #
***
control verapamil vinblastine vinblastine +verapamil
0
5
10
15
20
25
30
35
40
45
% a
popt
osis
HGT-1HGT-1-D5
![Page 5: Supplementary Figure 1](https://reader036.vdocuments.net/reader036/viewer/2022062423/56814901550346895db63154/html5/thumbnails/5.jpg)
Supplementary Figure 5
HGT-1 HGT-1-D5
Signal patterns
2O2G 3O3G 4O4G 3O1G
HGT-1 100
HGT-1-D5 42 47.5 8 2.5